Education
About Us
Working with TipRanks
Follow Us
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
RESEARCH TOOLSreports
Total Valuation
Contineum Therapeutics, Inc. Class A has a market cap or net worth of $106.33M. The enterprise value is $279.29M.
Market Cap$106.33M
Enterprise Value$279.29M
Share Statistics
Contineum Therapeutics, Inc. Class A has 19.14M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19.14M
Owned by Insiders0.97%
Owned by Instutions<0.01%
Financial Efficiency
Contineum Therapeutics, Inc. Class A’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -24.91%.
Return on Equity (ROE)-21.34%
Return on Assets (ROA)-19.85%
Return on Invested Capital (ROIC)-24.91%
Return on Capital Employed (ROCE)-25.09%
Revenue Per Employee$0
Profits Per Employee-$1,030,682.927
Employee Count41
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Contineum Therapeutics, Inc. Class A is -6.71. Contineum Therapeutics, Inc. Class A’s PEG ratio is 0.03.
PE Ratio-6.71
PS Ratio0.00
PB Ratio1.43
Price to Fair Value1.43
Price to FCF-8.50
Price to Operating Cash Flow-8.63
PEG Ratio0.03
Income Statement
In the last 12 months, Contineum Therapeutics, Inc. Class A had revenue of $0.00 and earned -$42.26M in profits. Earnings per share was -$1.73.
Revenue$0.00
Gross Profit-$121.00K
Operating Income$50.89M
Pretax Income-$42.26M
Net Income-$42.26M
EBITDA-42.00M
Earnings Per Share (EPS)-1.73
Cash Flow
In the last 12 months, operating cash flow was -$32.84M and capital expenditures -$514.00K, giving a free cash flow of -$33.36M billion.
Operating Cash Flow-$32.84M
Free Cash Flow-$33.36M
Free Cash Flow per Share-$1.74
Dividends & Yields
Contineum Therapeutics, Inc. Class A pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-11.77%
Earnings Yield-14.90%
Stock Price Statistics
Beta1.08
52-Week Price Change-71.71%
50-Day Moving Average6.87
200-Day Moving Average14.23
Relative Strength Index (RSI)29.59
Average Volume (3m)64.36K
Important Dates
Contineum Therapeutics, Inc. Class A upcoming earnings date is May 15, 2025, After Close.
Last Earnings DateMar 6, 2025
Next Earnings DateMay 15, 2025
Ex-Dividend Date―
Financial Position
Contineum Therapeutics, Inc. Class A as a current ratio of 20.69, with Debt / Equity ratio of 0.03
Current Ratio20.69
Quick Ratio20.69
Debt to Market Cap0.02
Net Debt to EBITDA0.31
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Contineum Therapeutics, Inc. Class A has paid $0.00 in taxes.
Income Tax$0.00
Effective Tax Rate0.00%
Enterprise Valuation
Contineum Therapeutics, Inc. Class A EV to EBITDA ratio is -5.26, with an EV/FCF ratio of -8.03.
EV to Sales0.00
EV to EBITDA-5.26
EV to Free Cash Flow-8.03
EV to Operating Cash Flow-8.15
Balance Sheet
Contineum Therapeutics, Inc. Class A has $204.76M in cash and marketable securities with $6.26M in debt, giving a net cash position of -$198.50M billion.
Cash & Marketable Securities$204.76M
Total Debt$6.26M
Net Cash-$198.50M
Net Cash Per Share-$10.37
Tangible Book Value Per Share$10.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Contineum Therapeutics, Inc. Class A is $23.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.75
Price Target Upside477.86%
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-100.00%
EPS Growth Forecast-244.85%